Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients.
about
Rosiglitazone for type 2 diabetes mellitusThiazolidinediones for type 2 diabetes. No evidence exists that pioglitazone induces hepatic cytochrome P450 isoform CYP3A4.Insulin sensitiser drugs.Insulin action enhancers for the management of type 2 diabetes mellitus.PPARgamma agonists in type 2 diabetes: how far have we come in 'preventing the inevitable'? A review of the metabolic effects of rosiglitazone.Free fatty acids--do they play a central role in type 2 diabetes?Insulin resistance and beta-cell function--a clinical perspective.Treating type 2 diabetes--today's targets, tomorrow's goals.Diabetes.Differentiating members of the thiazolidinedione class: a focus on efficacy.Where thiazolidinediones will fit.Redefining the clinical management of type 2 diabetes: matching therapy to pathophysiology.Counseling patients with type 2 diabetes and insulin resistance in the outpatient setting.Differential adoption of pharmacotherapy recommendations for type 2 diabetes by generalists and specialists.Glyburide/metformin tablets: a new therapeutic option for the management of Type 2 diabetes.Thiazolidinedione safety and efficacy in ambulatory patients receiving hemodialysis.Rosiglitazone plus metformin: combination therapy for Type 2 diabetes.Rosiglitazone RECORD study: glucose control outcomes at 18 months.Rosiglitazone and glimeperide: review of clinical results supporting a fixed dose combinationDyslipidaemia in type 2 diabetes: effects of the thiazolidinediones pioglitazone and rosiglitazone.Beta-cell preservation: a potential role for thiazolidinediones to improve clinical care in Type 2 diabetes.Protective effect of peroxisome proliferator activated receptor gamma agonists on diabetic and non-diabetic renal diseases.Future detection and monitoring of diabetes may entail analysis of both β-cell function and volume: how markers of β-cell loss may assist.Effects of glitazones in the treatment of diabetes and/or hyperlipidaemia: glycaemic control and plasma lipid levels.PPARs and the kidney in metabolic syndrome.Combination lipid therapy in type 2 diabetes mellitus.Pharmacologic treatment of type 2 diabetes: oral medications.Rosiglitazone monotherapy and type 2 diabetes.[Against insulin resistance. Insulin sensitizers].Rosiglitazone in Type 2 diabetes mellitus: an evaluation in British Indo-Asian patients.Management of the overweight patient with Type 2 diabetes.Chronic glucose-lowering effects of rosiglitazone and bis(ethylmaltolato)oxovanadium(IV) in ZDF rats.Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance.Rosiglitazone improves insulin sensitivity and glucose tolerance in subjects with impaired glucose tolerance.Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis.Rosiglitazone is a safe and effective treatment option of new-onset diabetes mellitus after renal transplantation.Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin.Effect of metformin plus roziglitazone compared with metformin alone on glycaemic control in well-controlled Type 2 diabetes.Comparison of antidiabetic drugs added to sulfonylurea monotherapy in patients with type 2 diabetes mellitus: A network meta-analysis
P2860
Q24243875-A49F0911-79F9-40A8-8DA2-4CB6F10D0B11Q28346358-81050439-516E-45A8-9718-95AEB5A40460Q34074912-68890913-932C-4423-BB6E-DC9AD2B63CCFQ34181849-3F65340F-E00E-4BF5-88ED-CF5C784BB6E6Q34421542-2B01C783-C0F5-42FE-9904-5CC302CB3D17Q34422774-95E55255-32BB-4EB3-9947-57D27FEAE325Q34422784-6628EB57-FE90-4EC3-8986-6B36AF941D0FQ34422790-64CF86A7-5181-45A8-8FF6-0C0577538E86Q34470314-67BD8A29-00C8-40FC-B622-3C0600463075Q34580989-69DB03A3-A5A1-4346-AF18-0C34DBCEFDD7Q34580999-CE101ABC-CB85-40D2-B0F8-41CB6F94C8B2Q34655587-B8B87085-B7AF-454A-B2E6-36DBBB9DE3B0Q35044470-C61CEC64-F489-4D1A-B6B3-9AF1E0F79643Q35151533-6A4A7AC0-A5D9-4C1A-8702-A23698EADB43Q35183780-F2F57133-D1E4-4B73-BBCD-0BD938261151Q35186537-6D791023-70EC-4B18-9CA6-3F94A1CFEA4CQ35784092-9C7BF0E5-F9CE-4C0E-9AA1-DD250A4A70D5Q35987411-694745DC-D265-4EFF-9209-0C04C5F3F4FBQ36013099-47AD33BC-6699-422B-BD76-949D33C95075Q36165296-EBC6F4CD-712D-4B4B-9631-FC64760AE96BQ36198965-F12CB12B-6E38-4313-9A9E-1AECEBAE65BDQ36262404-8D2E3038-6F72-4FB8-921D-458892378133Q36402230-D91B21CE-B179-4EB1-AA00-3F00490BF0E0Q37000784-7EAEAC17-DB52-41BA-95AA-DFF3ECF4D0F8Q37072216-9E6CFF7B-42DD-43D9-90FA-6DF04F9EEAD4Q37842472-9ABBADE5-170C-4B57-92E6-06105AFB964BQ38350347-4868EE2F-2B20-4960-9E6D-460E66E96D6CQ43978986-FDD0F0DC-D1CC-49CE-A4F6-2B42FA494D71Q44032476-ED381CE3-E580-49DA-9AFB-8E99422E5799Q44444547-1713EBF5-5F40-44B7-9F22-92EC8F972943Q44563264-9506AD2E-EAE6-4CD3-89A2-5405C2A1E234Q44725671-5F411481-E6E0-49C6-B7CB-258D6F4F1D84Q44847730-A6296A41-677C-4304-88BC-331DB22F136BQ45215924-1D8B39EA-A957-41AB-A3B5-71F6F87F3353Q46030058-2592269D-1223-4C0E-8EAE-F83529CA3551Q46386644-EB9CB4C1-47E6-4E17-A5D1-D9E9930E9632Q51480621-03082C71-0598-4349-9AAE-0CA7657F010EQ51489759-E3312EB9-E596-4233-913A-BB3B5F465AE9Q58701706-85E4CD45-F2EF-4244-9AE0-47641A2BC73F
P2860
Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh
2000年學術文章
@zh-hant
name
Addition of low-dose rosiglita ...... l in Type 2 diabetic patients.
@en
Addition of low-dose rosiglita ...... l in Type 2 diabetic patients.
@nl
type
label
Addition of low-dose rosiglita ...... l in Type 2 diabetic patients.
@en
Addition of low-dose rosiglita ...... l in Type 2 diabetic patients.
@nl
prefLabel
Addition of low-dose rosiglita ...... l in Type 2 diabetic patients.
@en
Addition of low-dose rosiglita ...... l in Type 2 diabetic patients.
@nl
P2093
P2860
P1433
P1476
Addition of low-dose rosiglita ...... l in Type 2 diabetic patients.
@en
P2093
Patwardhan RN
Squatrito S
P2860
P356
10.1046/J.1464-5491.2000.00224.X
P577
2000-01-01T00:00:00Z